Preoperative corrected CA 19-9 levels predict survival of patients with resected pancreatic cancer

Wei-Yi Wang,Wen-Jing Pang,Ping Chen,Xiao Su,Qi-Wen Ben,Yao-Zong Yuan

2016-01-01

Abstract:Serum carbohydrate antigen 19-9 (CA19-9) is a useful diagnostic marker of resectable pancreatic ductal adenocarcinoma (PDAC). However, CA19-9 may be artificially elevated. Corrected CA19-9 (cCA19-9) might enable accurate prognosis. Preoperative CA19-9 levels were measured and corrected CA19-9 were calculated in 189 patients who underwent surgical resection for PDAC between 2009 and 2013. Wilcoxon two-sample test, univariate and multivariate methods were used to analyze their relationship with clinicopathological factors and overall survival. Preoperative cCA19-9 was associated with pathologic stage and postoperative survival. Overall survival rates were significantly different between groups with different preoperative cCA19-9 cutoff values (200, 500, and 1000 U/ml), especially in the subgroup UICC stage II/III, which was divided into two groups based on a preoperative cCA19-9 cutoff value of 200 U/ml (P = 0.036). In multivariate analysis, preoperative cCA19-9 cutoff value of 200 U/ml (hazard ratio, 1.587; P = 0.014) and perineural invasion (hazard ratio, 1.477; P = 0.049) were independent predictors of prognosis. In conclusion,the study suggested that preoperative cCA19-9 cutoff value of 200 U/ml is an accurate prognostic factor in clinical staging of resectable PDAC. Preoperative cCA19-9 is a valuable tool for the determination of appropriate treatment for PDAC.